GlassScriptPhysician profile
Laura A Cinski
NPI 1003006198
$122,395.98
in general payments reported to CMS, 2019-2025
26 companies · $52K in 2025
The $52K reported for 2025 was more than what 96% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,052 · 2020: $1,723 · 2021: $22K · 2022: $13K · 2023: $14K · 2024: $18K · 2025: $52K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $67K · Honoraria: $5,706 · Consulting Fee: $4,878 · Food and Beverage: $4,077 · Travel and Lodging: $2,403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $67,292.50 |
| Honoraria | $5,705.50 |
| Consulting Fee | $4,878.00 |
| Food and Beverage | $4,077.11 |
| Travel and Lodging | $2,402.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $67,552.15 | 2021-2025 | |
| Pfizer INC. | $14,293.55 | 2023-2025 | |
| Biohaven Pharmaceuticals, INC. | $12,606.27 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $10,838.13 | 2022 | |
| Lilly USA, LLC | $5,843.37 | 2019-2023 | Emgality, Reyvow |
| Axsome Therapeutics, INC. | $4,165.26 | 2023-2025 | Symbravo, Sunosi |
| Lundbeck LLC | $3,253.52 | 2022-2025 | Vyepti |
| Allergan, INC. | $2,148.13 | 2019-2022 | |
| Amgen INC. | $415.53 | 2019-2024 | Aimovig |
| Supernus Pharmaceuticals, INC. | $274.97 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $269.02 | 2019-2024 | |
| Sunovion Pharmaceuticals INC. | $225.76 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $124.99 | 2019 | |
| Alexion Pharmaceuticals, INC. | $115.92 | 2019 | |
| Impel Pharmaceuticals INC. | $37.18 | 2023 | Trudhesa |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acorda Therapeutics, INC | $36.42 | 2020 | |
| Ucb, INC. | $35.04 | 2022 | |
| Impel Pharmaceuticals LLC | $25.30 | 2024 | Trudhesa |
| Sk Life Science, INC. | $24.91 | 2021 | |
| Harmony Biosciences LLC | $23.25 | 2022 | |
| Bausch Health US, LLC | $19.65 | 2019 | |
| Upsher-Smith Laboratories LLC | $18.80 | 2020 | |
| Amneal Pharmaceuticals LLC | $17.64 | 2022 | |
| Kyowa Kirin, INC. | $16.29 | 2020 | |
| Medtronic, INC. | $14.93 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Cinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.